Showing 8091-8100 of 10579 results for "".
- JAK Inhibitors Linked to Lower Adjunctive Therapy Use Than Dupilumab in ADhttps://practicaldermatology.com/news/jak-inhibitors-linked-to-lower-adjunctive-therapy-use-than-dupilumab-in-ad/2483122/Patients with atopic dermatitis (AD) treated with oral Janus kinase (JAK) inhibitors used fewer adjunctive therapies over the long term compared to those receiving dupilumab, according to a retrospective study published ahead of print in
- Review: Psoriasis May Increase Infection Risk After Hip Arthroplastyhttps://practicaldermatology.com/news/review-psoriasis-may-increase-infection-risk-after-hip-arthroplasty/2483053/Patients with psoriasis undergoing total hip arthroplasty (THA) may face a higher risk of postoperative infection, with evidence regarding total knee arthroplasty (TKA) outcomes remaining inconclusive, according to a new systematic review,
- Dual-Wavelength Laser Caps Gain Clinical Validation for Hair Density Gainshttps://practicaldermatology.com/news/dual-wavelength-laser-caps-gain-clinical-validation-for-hair-density-gains/2476121/KeraFactor announced that it will be spotlighting its dermatologist-developed hair health solutions this August in recognition of National Hair Loss Awareness Month, according to a news release from the manufacturer. The bran
- New Agreement Opens Premier Networks to TeleVox Techhttps://practicaldermatology.com/news/televox-and-premier-inc-announce-national-patient-engagement-agreement/2476115/TeleVox has announced a national group purchasing agreement with Premier, Inc. effective September 1, 2025, permiting Premier members to access negotiated pricing and terms for TeleVox offerings, including Digital Front Door, Appointment Management, Digital Care P
- Dr. Ted Rosen on JAK Inhibitors for Refractory Granulomatous and Autoimmune Dermatoseshttps://practicaldermatology.com/news/Dr-Ted-Rosen-JAK-Inhibitors-Refractory-Granulomatous-Autoimmune-Dermatoses/2476038/The role of JAK inhibitors in diseases characterized by chronic macrophage–T-cell interactions continues to grow, Theodore Rosen, MD, said at the DEF Essential Resource Meeting 2025 (DERM2025). The discussion focused on granuloma annulare (GA), sarcoidosis, lichen planus (LP), and lupus erythemat
- Dr. Ted Rosen Highlights Oral Lesions in Dermatologyhttps://practicaldermatology.com/news/Dr-Ted-Rosen-Highlights-Oral-Lesions-Dermatology/2476037/Oral lesions represent a diagnostic challenge in dermatology due to their limited morphological variation and overlapping features across conditions. At the DEF Essential Resource Meeting 2025 (DERM2025), Theodore Rosen, MD, reviewed a broad spectrum of oral pathologies, from benign pigmentations
- Report: IL-17 Therapies Target PsO and More, Poised for Growthhttps://practicaldermatology.com/news/report-il-17-therapies-target-pso-and-more-poised-for-growth/2475920/The interleukin-17 (IL-17) inhibitors market is expected to see sustained growth through 2034, driven primarily by next-gen agents and expanding indications in dermatology and rheumatology, according to a new report. Novel ag
- NPF and Boehringer Unite to Launch First GPP Awareness Dayhttps://practicaldermatology.com/news/NPF-Boehringer-Unite-Launch-First-GPP-Awareness-Day/2475890/Key Takeaways NPF and Boehringer Ingelheim launched a campaign to educate and support individuals with generalized pustular psoriasis.
- FDA Greenlights First Treatment for Chronic Hand Eczema in Adultshttps://practicaldermatology.com/news/fda-approves-first-treatment-for-chronic-hand-eczema-in-adults/2475816/The US Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream, making it the first and only treatment approved for adults with moderate-to-severe chronic hand eczema (CHE) who are unresponsive to topical corticosteroids or for those unsuitabl
- Long-Term Ixekizumab Use Not Linked to Increased Cancer Risk: Analysishttps://practicaldermatology.com/news/long-term-ixekizumab-use-not-linked-to-increased-cancer-risk/2475704/Long-term treatment with ixekizumab (IXE) for psoriasis, psoriatic arthritis, and axial spondyloarthritis was not associated with increased risk of malignant neoplasms, according to a new analysis of pooled data from 25 randomized clinical trials.